Code of Ethics

AIPES Code of Ethics
The sensitive nature of AIPES activities for the public, (i.e. human healthcare issues and radioactive hazards fear), implies at any time the risk of being the target of public inquiry and questioning. Moreover, AIPES wants to promote fair competition between its members. AIPES members should therefore at least fully comply with the EU and International legislation and principles related to:

  • Good Manufacturing Practice and Good Clinical Practice
  • Radioactive Transport Regulation
  • Radioprotection regulations for products or employees
  • Confidentiality of information
  • Patent protection
  • Fair Trade
  1. Each company should respect EU (and related EMEA and/or MDD guidelines) and local Good Manufacturing Practice (GMP) rules in the production of radiopharmaceuticals and medical equipment.
  2. Each company should respect EU (and related EMEA guidelines) and local GMP rules for the production of investigational Medical Products (IMP) for human use.
  3. IMP for human use should only be provided to customers within the framework of a clinical study or for compassionate use and, in any case, under express authorization from the competent authority responsible for IMP for human use
  4. No company shall sell, distribute or transport products from producers which do not respect EU and local GMP rules for the production of radiopharmaceuticals and medical equipment.
  5. No company shall sell, distribute or transport Investigational Medical Products (IMP) for human use not produced in laboratories, which are not authorized for IMP.
  6. Each company should strictly respect ADR regulations (European Agreement concerning the International Carriage of Dangerous Goods by Road) when transporting radiopharmaceuticals and IMP.
  7. Regarding their employees and products, each company should comply with ICRP (International Commission on Radiological Protection) and local radioprotection rules in the production, distribution and transportation of radiopharmaceuticals.
  8. Each company should report to AIPES any event that could trigger a crisis communication plan from the AIPES Executive Committee, in particular in view of avoiding potential EU-wide negative impact for the industry and/or customers.
  9. Each company should respect confidentiality of information and documents shared within AIPES, during and from AIPES meetings. Such confidential information cannot, in any case, be used against any AIPES member.
  10. Each company should comply with patents regulation.